- Home
- SGMT vs CCIF Comparison
SGMT vs CCIF Comparison
Compare SGMT & CCIF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGMT
- CCIF
- Stock Information
- Founded
- SGMT 2006
- CCIF 2011
- Country
- SGMT United States
- CCIF United States
- Employees
- SGMT N/A
- CCIF N/A
- Industry
- SGMT
- CCIF Finance/Investors Services
- Sector
- SGMT
- CCIF Finance
- Exchange
- SGMT Nasdaq
- CCIF Nasdaq
- Market Cap
- SGMT 128.5M
- CCIF 130.8M
- IPO Year
- SGMT 2023
- CCIF N/A
- Fundamental
- Price
- SGMT $3.72
- CCIF $6.98
- Analyst Decision
- SGMT Strong Buy
- CCIF
- Analyst Count
- SGMT 6
- CCIF 0
- Target Price
- SGMT $25.67
- CCIF N/A
- AVG Volume (30 Days)
- SGMT 315.0K
- CCIF 76.9K
- Earning Date
- SGMT 03-12-2025
- CCIF 01-01-0001
- Dividend Yield
- SGMT N/A
- CCIF 25.90%
- EPS Growth
- SGMT N/A
- CCIF N/A
- EPS
- SGMT N/A
- CCIF N/A
- Revenue
- SGMT N/A
- CCIF N/A
- Revenue This Year
- SGMT N/A
- CCIF N/A
- Revenue Next Year
- SGMT N/A
- CCIF N/A
- P/E Ratio
- SGMT N/A
- CCIF N/A
- Revenue Growth
- SGMT N/A
- CCIF N/A
- 52 Week Low
- SGMT $2.39
- CCIF $7.43
- 52 Week High
- SGMT $7.38
- CCIF $10.16
- Technical
- Relative Strength Index (RSI)
- SGMT 44.81
- CCIF 20.13
- Support Level
- SGMT $3.70
- CCIF $7.19
- Resistance Level
- SGMT $4.24
- CCIF $7.90
- Average True Range (ATR)
- SGMT 0.23
- CCIF 0.15
- MACD
- SGMT 0.04
- CCIF -0.05
- Stochastic Oscillator
- SGMT 45.70
- CCIF 4.17
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
About CCIF Carlyle Credit Income Fund Shares of Beneficial Interest
Carlyle Credit Income Fund is a non-diversified, closed-end management investment company. The Fund's primary investment objective is to generate current income, with a secondary objective to generate capital appreciation. The Fund seeks to achieve its investment objective by investing predominantly in equity and junior debt tranches of collateralized loan obligations, that are collateralized by a portfolio consisting mainly of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.